rights issue and capital raising, page-26

“The Rights Issue was designed to allow our existing shareholders priority access to this fund raising"

Directors took up around 12% of the $5.5m raised. I took up around 4.5% of the $5.5m as i expect us to go over Director Storks average price of 19c over the next 12-18 months.

Success so far with Multiple Myeloma and previous results for other indications indicates our human antibodies are superior to current non human antibodies which kill healthy cells. Being the only biotech capable of producing large batches of human antibodies is another thing making us unique in this sector and should be valued highly.